先端巨大症治療の世界市場-2023年～2030年

概要

世界の先端巨大症治療市場は、2022年に12億米ドルに達し、2023-2030年の予測期間にCAGR 7.4％で成長し、2030年には21億米ドルに達すると予測されています。

先端巨大症治療市場の動向は、技術的進歩や調査研究の増加に起因する研究の上昇を示しています。先端巨大症の治療薬として、いくつかのソマトスタチン類似体が上市されています。成長ホルモン受容体作動薬も先端巨大症治療の予防に利用されています。

さらに、承認されたソマトスタチン類似体の入手可能性の上昇と市場における先端巨大症患者数の増加による先端巨大症治療の増加、および研究開発の増加が、先端巨大症治療市場規模を押し上げています。

この分野での進歩の高まりにより、北米地域の医薬品需要が伸びています。Recordati Rare Diseases社、Pfizer Inc.社、Validus Pharmaceuticals LLC社、Amryt Pharma plc社などの競合企業が積極的に市場に参入しているため、市場は今後成長すると思われます。

ダイナミクス

主要企業による新製品上市の増加が先端巨大症治療市場の成長を牽引

先端巨大症は、成長ホルモン（GH）の過剰分泌によって引き起こされる珍しい疾患です。年齢を問わず誰にでも発症する可能性がありますが、通常は30～50歳の成人に発症します。この疾患は、骨や組織の急速な発育に加え、その他多くの症状を特徴とします。現在、いくつかの研究が進行中であり、さまざまな臨床試験で良好な結果が得られています。

例えば、2021年7月15日、欧州で複合型医薬品に積極的に取り組んでいる専門医薬品企業であるアドバンズファーマ社のリリースによると、ドイツでは、先端巨大症、グレード1およびグレード2の消化器膵神経内分泌腫瘍のサブセット、神経内分泌腫瘍に関連する症状が、初のランレオチドジェネリックであるMYTOLAC（ランレオチド）の治療対象となります。

また、手術や放射線治療後も成長ホルモンやインスリン様成長因子-1（IGF-1）の循環量に異常がある先端巨大症の患者や、その他の状況で医療的ケアが必要な患者の治療にも使用されます。以上のような要因が先端巨大症市場の成長を牽引しています。

企業による注意喚起への取り組みの高まりが市場成長の機会を生み出す

多くの人々が先端巨大症やその治療法について知らないため、診断が遅れ、合併症を引き起こしています。現在、いくつかの大手企業が先端巨大症治療のための治療法を開発しているが、それとともに、先端巨大症治療市場におけるアンメット・ニーズについて議論するウェビナーを開催することで、人々や他の企業の間で認知度を高めています。

例えば、2023年7月10日、KOL（Key Opinion Leader）ウェビナーがClinetics Pharmaceuticals, Inc.によって開催され、KOLであるハーバード大学医学部教授のBeverly M.K. Biller氏と研究調査コーディネーターのKaren J.P. Liebert, R.N., BSN氏がプレゼンテーションを行っています。両氏は、先端巨大症の現状、この疾患における医療上のアンメットニーズ、現在の標準治療であるSRL注射剤による治療の難しさについて説明しました。

クリネティクスの経営陣は、1日1回経口投与可能な低分子ソマトスタチン受容体2型作動薬であるパルツソチンの第3相PATHFNDR-1試験と、同社が社内で開発した経口低分子治療薬候補のパイプラインに重点を置いた。

先端巨大症治療薬に伴う副作用が市場の成長を妨げる

先端巨大症治療薬は一般的に大量に服用する必要があるため、副作用の可能性が高くなります。これらの薬剤は、吐き気、嘔吐、鼻づまり、疲労感、めまい、睡眠障害、気分の落ち込みなどを頻繁に引き起こします。パーキンソン病患者において、ドーパミン作動薬（DA）を非常に大量に使用すると、心臓弁機能不全のリスクが高まることが判明しています。

横断的調査では、カベルゴリンで治療された高プロラクチン血症患者や先端巨大症患者において、このことは証明されていません。心血管系や呼吸器系の問題が先端巨大症に関連している場合には、手術の数カ月前からSAを投与したほうが好ましいです。これらの上記の要因は、市場の成長を抑制する可能性があります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 主要企業による新製品上市の増加
    • 先端巨大症治療の普及率上昇
  • 抑制要因
    • 先端巨大症治療薬に伴う副作用
  • 機会
    • 注意力発達のための企業間のイニシアティブの高まり
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 規制分析

第6章 COVID-19分析

第7章 医薬品別

• ソマトスタチン類似体
  • ランレオチド
  • オクトレオチド
• 成長ホルモン受容体拮抗薬
  • ペグビソマント
  • テプロツムマブ
• ドーパミン作動薬
  • ブロモクリプチン
  • カベルゴリン
• 併用療法

第8章 投与経路別

• 経口
• 皮下投与
• その他

第9章 流通チャネル別

• 病院薬局
• 小売薬局
• オンライン薬局

第10章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • オーストラリア
  • その他アジア太平洋
• 中東・アフリカ

第11章 競合情勢

• 競合シナリオ
• 市況/シェア分析
• M&A分析

第12章 企業プロファイル

• Recordati Rare Diseases
  • 企業概要
  • 製品ポートフォリオと説明
  • 財務概要
  • 主な動向
• Pfizer Inc.
• Validus Pharmaceuticals LLC
• Ipsen Pharma
• Crinetics Pharmaceuticals, Inc.
• Amryt Pharma plc
• Debiopharm
• ADVANZ PHARMA
• Novartis Pharmaceuticals Corporation
• Amolyt Pharma

第13章 付録

Overview

The global acromegaly treatment market reached US$ 1.2 billion in 2022 and is expected to reach US$ 2.1 billion by 2030 growing with a CAGR of 7.4% during the forecast period 2023-2030.

The acromegaly treatment market trends show rising research owing to the rising technological advancements and research studies. Several somatostatin analogs are being launched for the treatment of acromegaly. Growth hormone receptor agonists are also utilized for prevention of acromegaly treatment.

Furthermore, rising treatment for acromegaly due to the rising availability of approved somatostatin analogs and increase in the number of acromegaly cases in the market, and an increase in the research and development is driving up the acromegaly treatment market size.

The market is experiencing a growth in demand for drugs from North America areas as a result of the rising advancements in this field. With significant competitors like Recordati Rare Diseases, Pfizer Inc., Validus Pharmaceuticals LLC, and Amryt Pharma plc actively operating in the market, the market will grow in upcoming time.

Dynamics

Growing Novel Product Launches by the Key Players Drive the Growth of the Acromegaly Treatment Market

Acromegaly is an uncommon condition brought on by oversecretion of the growth hormone (GH). Although it can affect anyone at any age, it is typically diagnosed in adults between the ages of 30 and 50. It is characterized by rapid bone and tissue development in addition to an extensive number of other symptoms. Several researches are currently undergoing and various clinical trials are showing positive outcomes resulting in launch of novel products in the market for treatment of acromegaly.

For instance, on July 15, 2021, according to a release from ADVANZ PHARMA, a specialty pharmaceutical business with an aggressive emphasis on complex medicines in Europe, acromegaly, grade one and a subset of grade two gastroenteropancreatic neuroendocrine tumors, and symptoms related to neuroendocrine tumors are all conditions that MYTOLAC (lanreotide), the first generic lanreotide, will be used to treat, in Germany.

treatment of people with acromegaly when circulating amounts of Growth Hormone or Insulin-like Growth Factor-1 (IGF-1) are still abnormal after surgery and/or radiotherapy, or in patients who need medical attention in any other situation. These above mentioned factors are leading to drive the growth of the acromegaly market.

Rising Initiatives Among Companies for Developing Attention Creates Opportunities for the Growth of the Market

Numerous people are unaware of acromegaly and its treatment hence its diagnosis gets delayed leading to complications. Several major companies are currently developing therapies for acromegaly treatment along with this they are creating awareness among people and other companies by organizing webinars in which they discuss about the unmet needs in the acromegaly treatment market.

For instance, on July 10, 2023, the Key Opinion Leader (KOL) webinar was held by Crinetics Pharmaceuticals, Inc. and featured presentations by KOLs Beverly M.K. Biller, a Harvard Medical School professor of medicine and Karen J.P. Liebert, R.N., BSN, a research study coordinator, both are faculty members of Massachusetts General Hospital. They covered the current state of acromegaly, unmet medical needs in the condition, and the difficulties in treating it with injectable SRLs, which are currently the standard of care.

A emphasis was placed on the Phase 3 PATHFNDR-1 study of paltusotine, an experimental, somatostatin receptor type 2 agonist which is orally administered, once-daily small molecule, by the Crinetics management team as well as the company's pipeline of internally developed oral small molecule therapeutic candidates.

Side Effects Associated with the Acromegaly Treatment Medications will Hamper the Growth of the Market

These drugs generally require to be taken in large amounts for treating acromegaly, that raises the chances of side effects. These medications frequently cause nausea, vomiting, stuffy noses, fatigue, dizziness, sleep issues, and mood swings. The risk of heart valve dysfunction has been found to increase with the use of very high dosages of dopamine agonists (DAs) in Parkinson's disease patients.

In the cross-sectional research, this has not been demonstrated in hyperprolactinemic individuals or acromegalic individuals treated with cabergoline. It is better to administer a SA for a few months before to surgery when cardiovascular or respiratory issues are connected to acromegaly. These above mentioned factors may restrain the growth of market.

For more details on this report - Request for Sample

Segment Analysis

The global acromegaly treatment market is segmented based on drugs, route of administration and distribution channel.

Owing to High Utilization, the Somatostatin Analogs from Treatment Segment Accounted for Approximately 41.8% of the Acromegaly Treatment Market Share

The somatostatin analogs category from treatment held the largest market share in 2022 and is expected to maintain its dominance over the forecast period due to a growth in incidence of acromegaly worldwide. Native somatostatin has a variety of physiological effects, including as its function as a neurotransmitter and neuromodulator in the central nervous system, a regulatory hormone in the pancreas and gastrointestinal tract, and an inhibitor of GH and TSH production in the pituitary.

Native somatostatin continues to suppress GH secretion in numerous GH-secreting tumors in vitro, which prompted the creation of somatostatin analogs for usage in clinical settings to treat acromegaly. The cyclic octapeptides lanreotide (Dnal-cys-tyr-Dtrp-lys-val-cys-thr) or octreotide (Dphe-cys-phe-Dtrp-lys-thr-cys-thr-ol) are the two somatostatin analogs that are now used in medicine. The only analog now used in clinical settings to treat acromegaly in the United States is octreotide.

In Europe, lanreotide is frequently employed to treat acromegaly. These analogs have certain advantages over the native hormone for treating acromegaly, such as better efficacy for GH suppression and a longer half-life following peripheral delivery than somatostatin. For instance, when administered subcutaneously, octreotide has a half-life of 2 hours and is 45 times more effective than native somatostatin at inhibiting pituitary GH secretion.

Geographical Penetration

North America Accounted for Approximately 37.7% of the Market Share in 2022, Owing to the Strong Presence of Major Players and Increasing Healthcare Infrastructure Investment

Due to the rising need for acromegaly treatment in healthcare, manufacturers in North America have chances of increasing their operations. There are many producers and suppliers in North America and owing to the quick economic growth of the region, industrial production has expanded, driving the demand for drugs for acromegaly treatment.

Increasing expenditure on healthcare and rising research studies, advancement of technologies for treatment of rare disease, and increase in pharmaceutical and biotechnology business establishment across the region are also contributing to the growth of acromegaly treatment market share of this region.

It is also anticipated that the main healthcare organizations' and enterprises' collaborative research projects as well as new product development, which constantly seeks to improve available alternatives, will contribute to the expanding demand. Individuals are becoming more aware of various drugs such as somatostatin analogs for subcutaneous usage for management purposes, leading to the expansion of the market in this region. The above-mentioned factors further proves the dominance of North America on a global scale.

Competitive Landscape

The major global players in the acromegaly treatment market include: Recordati Rare Diseases, Pfizer Inc., Validus Pharmaceuticals LLC, Ipsen Pharma, Crinetics Pharmaceuticals, Inc., Amryt Pharma plc, Debiopharm, ADVANZ PHARMA, Novartis Pharmaceuticals Corporation and Amolyt Pharma among others.

COVID-19 Impact Analysis

Russia Ukraine Conflict Analysis

Due to the low prevalence as well as absence of major market participants in this region, it is predicted that the Russia-Ukraine conflict will not have a significant effect on the worldwide acromegaly treatment market. The growth of the global acromegaly treatment market, however, is anticipated to be relatively unaffected by the import and export of raw materials over the forecast period.

By Drugs

• Somatostatin Analogs
  • Lanreotide
  • Octreotide

• Growth Hormone Receptor Antagonists
  • Pegvisomant
  • Teprotumumab

• Dopamine Agonists
  • Bromocriptine
  • Cabergoline

• Combination Therapy

By Route of Administration

• Oral
• Subcutaneous
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region

• North America
  • U.S.
  • Canada
  • Mexico

• Europe
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Rest of Europe

• South America
  • Brazil
  • Argentina
  • Rest of South America

• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific

• Middle East and Africa

Key Developments

• On December 5, 2022, the European Commission (EC) has approved Mycapssa in the European Union (EU) for continuing the treatment of acromegaly for individuals who have responded to and adapted to treatment with octreotide or lanreotide, according to Amryt, a multinational, commercial-stage biopharmaceutical business dedicated to acquiring, developing, and commercializing new therapies for rare diseases. For individuals with acromegaly who responded well to treatment using injectable lanreotide or octreotide, mycapssa is already licensed in the United States for ongoing maintenance treatment.
• On March 16, 2022, Ipsen said that it will invest in a brand-new, cutting-edge electronic autoinjector for Somatuline Autogel or Somatuline Depot (lanreotide) in order to advance the field's innovation and enhance patient administration and injection experiences. Together with increased investment in Ipsen's Signes manufacturing facility in France, Phillips-Medisize, a global leader in drug-delivery design, development, and manufacturing solutions, will work on the new device.
• On November 11, 2021, Acromegaly, grade one as well as a subset of grade two gastroenteropancreatic neuroendocrine tumors, and symptoms related to neuroendocrine tumors are all conditions that MYRELEZ (lanreotide), the first generic lanreotide, will be used to treat, in Norway, this announcement was made by ADVANZ PHARMA, a specialty pharmaceutical business with an aggressive emphasis on complex medicines in Europe.

Why Purchase the Report?

• To visualize the global acromegaly treatment market segmentation based on drugs, route of administration, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of acromegaly treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global acromegaly treatment market report would provide approximately 53 tables, 54 figures and 195 Pages.

DMI Opinion:

The global acromegaly treatment market is going to see moderate growth in upcoming years owing to rising usage of somatostatin analogs for acromegaly treatment. Several researches are taking place worldwide for somatostatin analogs development. Numerous advances are taking place leading to the growth of market such as novel somatostatin analogs. According to DMI the acromegaly treatment market will see a decent growth with several novel therapies in the market.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Drugs
• 3.2. Snippet by Route of Administration
• 3.3. Snippet by Distribution Channel
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Growing Novel Product Launches by the Key Players
    • 4.1.1.2. Rising Prevalence of Acromegaly Treatment
  • 4.1.2. Restraints
    • 4.1.2.1. Side Effects Associated with the Acromegaly Treatment Medications
  • 4.1.3. Opportunity
    • 4.1.3.1. Rising Initiatives Among Companies for Developing Attention
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Forces Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Scenario Before COVID-19
  • 6.1.2. Scenario During COVID-19
  • 6.1.3. Scenario Post COVID-19
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. By Drugs

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
  • 7.1.2. Market Attractiveness Index, By Drugs
• 7.2. Somatostatin Analogs *
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.2.3. Lanreotide
  • 7.2.4. Octreotide
• 7.3. Growth Hormone Receptor Antagonists
  • 7.3.1. Pegvisomant
  • 7.3.2. Teprotumumab
• 7.4. Dopamine Agonists
  • 7.4.1. Bromocriptine
  • 7.4.2. Cabergoline
• 7.5. Combination Therapy

8. By Route of Administration

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 8.1.2. Market Attractiveness Index, By Route of Administration
• 8.2. Oral *
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Subcutaneous
• 8.4. Other

9. By Distribution Channel

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.1.2. Market Attractiveness Index, By Distribution Channel
• 9.2. Hospital Pharmacies *
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Retail Pharmacies
• 9.4. Online Pharmacies

10. By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
  • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.2.6.1. U.S.
    • 10.2.6.2. Canada
    • 10.2.6.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
  • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.3.6.1. Germany
    • 10.3.6.2. U.K.
    • 10.3.6.3. France
    • 10.3.6.4. Spain
    • 10.3.6.5. Italy
    • 10.3.6.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 12.4.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnosis
  • 12.4.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
  • 12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 12.4.5.1. Brazil
    • 12.4.5.2. Argentina
    • 12.4.5.3. Rest of South America
• 10.5. Asia-Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
  • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.5.6.1. China
    • 10.5.6.2. India
    • 10.5.6.3. Japan
    • 10.5.6.4. Australia
    • 10.5.6.5. Rest of Asia-Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
  • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

• 11.1. Competitive Scenario
• 11.2. Market Positioning/Share Analysis
• 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

• 12.1. Recordati Rare Diseases *
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio and Description
  • 12.1.3. Financial Overview
  • 12.1.4. Key Developments
• 12.2. Pfizer Inc.
• 12.3. Validus Pharmaceuticals LLC
• 12.4. Ipsen Pharma
• 12.5. Crinetics Pharmaceuticals, Inc.
• 12.6. Amryt Pharma plc
• 12.7. Debiopharm
• 12.8. ADVANZ PHARMA
• 12.9. Novartis Pharmaceuticals Corporation
• 12.10. Amolyt Pharma

LIST NOT EXHAUSTIVE

13. Appendix

• 13.1. About Us and Services
• 13.2. Contact Us